PUYOU DE POUVOURVILLE Gérard, Szafranski Kirk, Greenberg Dan, Harris Stewart, Jendle Johan, Shaw Jonathan E., Castro JeanPierre Coaquira, Poon Yeesha, Levrat-Guillen Fleur
Existing cost-effectiveness models in diabetes are useful, but they are not suitable for all health technology assessment (HTA) agencies. The Determination of Diabetes Utilities, Costs, and Effects (DEDUCE) model was developed to better meet the needs of those HTA agencies. To assess the accuracy and validity of the DEDUCE model in type 1 and type 2 diabetes. DEDUCE predicts diabetes-related complications well when compared with previously validated cost-effectiveness models. DEDUCE is suitable to assess the cost-effectiveness of diabetes technologies for HTA submissions.
SZAFRANSKI, K., PUYOU DE POUVOURVILLE, G., GREENBERG, D., HARRIS, S., JENDLE, J., SHAW, J.E. … LEVRAT-GUILLEN, F. (2024). The Determination of Diabetes Utilities, Costs, and Effects Model, A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation. Value in Health, In press, pp. 8.